Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Form 8.5 (EPT/RI)

29 May 2018 16:38

RNS Number : 5841P
Canaccord Genuity Limited
29 May 2018
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Canaccord Genuity Limited

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Vernalis Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Connected party to the Offeree

 

(d) Date dealing undertaken:

25 May 2018

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

No

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

Ord 1p

 

 

Buy

200

 

7p

 

 

7p

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

NONE

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

NONE

 

Date of disclosure:

29 May 2018

Contact name:

Sam Cooke

Telephone number:

020 7523 4658

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERFMGZKKLVGRZM
Date   Source Headline
6th Mar 20125:29 pmRNSHolding(s) in Company
5th Mar 20125:39 pmRNSHolding(s) in Company
2nd Mar 20129:22 amRNSVoting Rights and Capital
28th Feb 201212:28 pmRNSResult of General Meeting
28th Feb 20127:00 amRNSResult of Open Offer
10th Feb 20124:53 pmRNSPublication of Combined Circular and Prospectus
10th Feb 20127:00 amRNSLicence Agreemt &Firm Placing &Placing &Open Offer
10th Feb 20127:00 amRNSVernalis and Tris Pharma Announce Collaboration
17th Jan 20127:00 amRNSVernalis & Servier Sign 3rd Oncology Collaboration
4th Jan 20127:00 amRNSVernalis enters collaboration with Genentech
19th Dec 20117:00 amRNSSecond Research Milestone Achieved
12th Dec 20117:00 amRNSVernalis Earns Final Milestone Payment from Ipsen
16th Nov 20117:00 amRNSInterim Management Statement
7th Nov 201111:43 amRNSHolding(s) in Company
3rd Oct 20117:00 amRNSMilestone Achieved and Collaboration Extended
28th Sep 20117:00 amRNSPositive Results for V158866 in Phase I Study
21st Sep 20117:00 amRNSResearch Milestone Achieved
8th Sep 20114:40 pmRNSSecond Price Monitoring Extn
8th Sep 20114:35 pmRNSPrice Monitoring Extension
24th Aug 20117:00 amRNSVernalis Initiates Phase I Trial of V81444
17th Aug 20115:16 pmRNSReplacement - Director/PDMR Shareholding
17th Aug 20114:35 pmRNSDirector/PDMR Shareholding
12th Aug 201110:00 amRNSDirector/PDMR Shareholding
5th Aug 201111:59 amRNSHolding(s) in Company
3rd Aug 20117:00 amRNSInterim results for six months ended 30 June 2011
3rd Aug 20117:00 amRNSAppointment of Non-Executive Director
2nd Aug 201111:30 amRNSVernalis Appoints Corporate Broker
22nd Jul 20117:00 amRNSNotice of Results for Six Months Ended 30 June '11
20th Jul 20117:00 amRNSAUY922 Update
5th Jul 20114:40 pmRNSSecond Price Monitoring Extn
5th Jul 20114:35 pmRNSPrice Monitoring Extension
15th Jun 201111:30 amRNSResult of AGM
8th Jun 20114:20 pmRNSHolding(s) in Company
26th May 20114:41 pmRNSSecond Price Monitoring Extn
26th May 20114:35 pmRNSPrice Monitoring Extension
26th May 20114:17 pmRNSListing Application, Voting Rights, Share Capital
23rd May 20114:58 pmRNSHolding(s) in Company
19th May 20114:40 pmRNSSecond Price Monitoring Extn
19th May 20114:35 pmRNSPrice Monitoring Extension
13th May 20117:00 amRNSTosedostat data to be presented at ASCO
11th May 20117:00 amRNSInterim Management Statement
6th May 20117:01 amRNSDirector/PDMR Shareholding
6th May 20117:00 amRNSDirector/PDMR Shareholding
4th May 20117:01 amRNSAnnual Information Update
4th May 20117:00 amRNSNotice of AGM
20th Apr 201111:57 amRNSHolding(s) in Company
12th Apr 20114:40 pmRNSSecond Price Monitoring Extn
12th Apr 20114:35 pmRNSPrice Monitoring Extension
12th Apr 20117:00 amRNSResults for the year ended 31 December 2010
12th Apr 20117:00 amRNSVernalis Regains A2A Receptor Antagonist Programme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.